ITI Senior Director of Corporate Development to Participate in an All Women’s Leadership Panel Discussion and Dinner at ISPE’s First Women in Pharma Event

ROCKVILLE, Md.--()--Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD. The panel will consist of women within the biotech industry. ISPE Women in Pharma® (WIP) provides women in the pharmaceutical industry a forum for connecting and collaborating on technical and career advancement topics.

Panel participants include:

  • Sia Anagnostou, Senior Director of Corporate Development, Immunomic Therapeutics
  • Shiva Frietsch, Sr. Vice President HR, RegenxBIO
  • Marcella Goodnight, Director, Global Technical Operations, AstraZeneca Biologics
  • Dr. Katherine Sacksteder, PhD, COO, Benevir Biopharm Inc.
  • Dr. Judy Steveley, Program Director Bioprocessing Technology, Assistant Professor, Frederick Community College
  • Moderator: Shannah Falcone, Senior Associate / Director Strategic Accounts, CRB

Who: Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou

What: ISPE’s Women in Pharma Panel Discussion

When: Tuesday, March 27, 4-7:40 p.m. EDT

Where: Montgomery College, Pinkney Innovation Complex: Science and Technology, 20200 Observation Drive, Gaithersburg, MD

About LAMP-Vax

ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the investigational LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and its investigational LAMP Technology, visit www.immunomix.com.

Contacts

Immunomic Therapeutics (ITI)
Sia Anagnostou
717-327-1822

Release Summary

Immunomic Therapeutics' Senior Director of Corporate Development, Sia Anagnostou, to participate as a panelist in the ISPE's Women in Pharma event.

Contacts

Immunomic Therapeutics (ITI)
Sia Anagnostou
717-327-1822